title: [Mutations of HBV polymerase gene sequence in lamivudine-resistant chronic hepatitis B patients].
abstract: OBJECTIVE
  To explore the characteristics of mutation in HBV polymerase (P) gene reverse transcriptase region (RT region) in lamivudine-resistant chronic hepatitis B (CHB) patients.
  
  
  METHODS
  This study involved 115 CHB patients who developed clinical resistance to lamivudine. Direct sequencing of the PCR products was used to detect lamivudine genotypic resistance.
  
  
  RESULTS
  Lamivudine resistant mutation was detected in 103 patients, and the major mutations included rtL180M+rtM204V and rtM204I, accounting for 58.3% and 22.3%, respectively. Other resistant substitutions included rtL80V/I, rtT184S, and rtA200V, and combined mutation of triple resistant substitutions was detected in HBV RT region of 5 patients by direct sequencing.
  
  
  CONCLUSIONS
  For lamivudine-treated patients, combined mutation at the sites other than rtL180 and rtM204 in HBV P gene should also be detected for drug resistance evaluation.
authors.affiliation: Department of Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. doc_chengwang@126.com
authors.forename: Cheng
authors.initials: C
authors.lastname: Wang
authors.forename: Jian
authors.initials: J
authors.lastname: Sun
authors.forename: Jin-jun
authors.initials: JJ
authors.lastname: Chen
authors.forename: Zhan-hui
authors.initials: ZH
authors.lastname: Wang
authors.forename: Jin-lin
authors.initials: JL
authors.lastname: Hou
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics*; D015684:Gene Products, pol / Q000235:genetics*; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D009154:Mutation
chemical_list: D019380:Anti-HIV Agents; D015684:Gene Products, pol; C066027:P protein, Hepatitis B virus; D019259:Lamivudine